Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials
A pharmacy that compounds semaglutide with three additional ingredients should have stability data for that specific combination, not just for semaglutide alone
Patients should be counselled to report symptoms such as chest pain, palpitations, or unexplained shortness of breath promptly
People are fully aware of what is happening internationally, said Goel, who has worked on obesity-related ailments for 24 years
They used monomethyl auristatin E which is known microtubule-disrupting agent
Safety risks include immune reactions, infections at the injection site, disruptions to metabolism, effects on hormone signalling and cardiac function, and the promotion of tumour growth